Atypical Antipsychotics

  • Bart A. Ellenbroek
  • Alexander R. Cools

Part of the Milestones in Drug Therapy MDT book series (MDT)

Table of contents

  1. Front Matter
    Pages I-XI
  2. A general introduction

    1. Front Matter
      Pages 1-1
    2. Peter F. Liddle
      Pages 3-17
    3. John L. Waddington, John F. Quinn
      Pages 19-33
    4. Bart A. Ellenbroek, Alexander R. Cools
      Pages 35-53
  3. The preclinical evaluation of atypical antipsychotics

    1. Front Matter
      Pages 55-55
    2. Josée E. Leysen
      Pages 57-81
    3. Bart A. Ellenbroek, Alexander R. Cools
      Pages 83-98
    4. Bart A. Ellenbroek, Frank Sams-Dodd, Alexander R. Cools
      Pages 121-142
  4. The clinical evaluation of atypical antipsychotics

    1. Front Matter
      Pages 143-143
    2. Dieter Naber, Christian Haasen, Christian Perro
      Pages 145-162
    3. Johan A. Den Boer, Jakob Korf
      Pages 163-190
    4. Herbert Y. Meltzer
      Pages 191-213
  5. Back Matter
    Pages 233-236

About this book


The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.


dopamine research schizophrenia serotonin therapy

Editors and affiliations

  • Bart A. Ellenbroek
    • 1
  • Alexander R. Cools
    • 1
  1. 1.Dept. of PsychoneuropharmacologyUniversity of NijmegenNijmegenThe Netherlands

Bibliographic information

Industry Sectors
Health & Hospitals